Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03242213
Other study ID # 6680
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 20, 2017
Est. completion date September 9, 2019

Study information

Verified date January 2021
Source Advocate Health Care
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current randomized controlled trial is a pilot study that will assess the effectiveness and feasibility of a mobile phone application intervention. The objective is to determine whether the use of a mobile health application for patient self-management of depression improves patient-provider engagement for patients diagnosed with major depressive disorder.


Description:

This pilot study will be a randomized, real-world effectiveness study. Patients diagnosed with major depressive disorder starting a new prescription for an antidepressant monotherapy will be eligible for participation. The study will enroll 40 patients (20 in an observational arm of usual care and 20 with access to a mobile health application). No intervention will occur in the usual care arm. The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression. Patient reported outcomes and clinical data will be collected at baseline and at study primary endpoint (18 weeks) to assess changes over time and between groups for: patient-provider engagement, disease severity, quality of life, employment productivity, cognitive function, resource utilization, and medication adherence. Additionally, resource utilization will be assessed at the one year time point. A Student's t test, if allowed for by the data distribution, will be used to assess between group differences in patient reported outcome scales assessing patient-provider engagement.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 9, 2019
Est. primary completion date January 18, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Age 18 to 70 - Ability to consent and participate in study (technical requirements for app: iPhone version 5 or later, active data plan or regular WiFi access) - Diagnosis with major depressive disorder - PHQ-9 score greater than 5 at baseline - Recent (0-14 days) start on monotherapy depression medication (either new prescription or a change from a previous medication) - Outpatient care provided by participating Advocate Medical Group clinics Exclusion Criteria: - Diagnosis with major psychiatric disorder (e.g. bipolar disorder, manic depressive disorder) - Contraindications to use of depression medications - Patients with treatment resistant depression [defined as patients who have not responded to two or more separate different antidepressant monotherapy trials of adequate dose and duration (6 weeks or longer) in the current depressive episode] - Considered at imminent risk for hospitalization due to severe depression in the opinion of the treating physician - History of hospitalization due to major depressive disorder in prior 3 months - Significant risk of suicide according to the treating physician's clinical judgment or previous suicide attempt in prior 6 months - History of response only to combination or augmentation therapy in current depressive episode - Receipt of any investigational compound in prior 30 days (or five half-lives, whichever is longer) - Current participation in another clinical study - Lack of functional English literacy

Study Design


Intervention

Behavioral:
Mobile App
The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.

Locations

Country Name City State
United States Advocate Christ Medical Center Oak Lawn Illinois

Sponsors (2)

Lead Sponsor Collaborator
Advocate Health Care Takeda

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Long-term follow health care utilization This patient reported outcome is assessed by the healthcare resource utilization and cost RUQ-D survey. 1 year
Primary Patient activation This will be assessed by the Patient Activation Measure, a validated scale that measures patient knowledge, skills and confidence in disease self-management in the primary care setting. 18 weeks
Primary Patient-provider engagement This will be assessed by the Patient-Provider Engagement Scale (PPES-7), an instrument developed for this study to measure patient knowledge, communication, and interaction with their provider specific to depression management. 18 weeks
Secondary Depression symptoms This patient reported outcome is assessed by the clinical depression severity. PHQ-9 scale, which scores each of the nine DSM-IV criteria as "0" (not at all) to "3" (nearly every day). 18 weeks
Secondary Cognitive dysfunction This patient reported outcome is assessed by the cognitive dysfunction PDQ-D scale. 18 weeks
Secondary Medication changes This outcome will be assessed by clinical data on the frequency and types of medication switches. 18 weeks
Secondary Quality of Life This patient reported outcome is assessed by the quality of life WHO-5 survey. 18 weeks
Secondary Health care utilization This patient reported outcome is assessed by the healthcare resource utilization and cost RUQ-D survey. 18 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4